10% Owner Buys $721K in Shares Following Merger Announcement
INM has more than doubled off its 52-week low of $0.575.
Summary
A 10% owner made a substantial $721,548 open market purchase of InMed Pharmaceuticals shares, coinciding with the announcement of the company's merger with Mentari Therapeutics.
Key Events · Ownership and Investor Activity · INM
-
Significant Insider Purchase
ADAR1 Capital Management, LLC and Daniel Schneeberger, a 10% owner, acquired 468,551 common shares for a total of $721,548 in open market transactions.
-
Post-Merger Announcement Timing
The purchases occurred on May 19, 2026, the same day InMed Pharmaceuticals announced an all-stock merger agreement with privately-held Mentari Therapeutics.
-
Substantial Investment Relative to Market Cap
The $721,548 purchase represents a significant investment, equivalent to over 12% of InMed Pharmaceuticals' current market capitalization.
Analysis · INM · Life Sciences
A significant open market purchase by a 10% owner, ADAR1 Capital Management, LLC and Daniel Schneeberger, totaling over $721,000, occurred on the same day InMed Pharmaceuticals announced its all-stock merger with Mentari Therapeutics. This substantial investment, representing over 12% of the company's market capitalization, suggests a vote of confidence in the company's new strategic direction and the potential of the combined entity, especially given InMed's recent financial challenges and going concern warnings.
At the time of this filing, INM was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $0.58 to $7.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.